CPT1B rs470117: Lipid Metabolism & Training Efficiency
The rs470117 polymorphism is a common single nucleotide variation situated within the CPT1B gene on chromosome 22. This gene encodes the muscle isoform of carnitine palmitoyltransferase 1, the gatekeeping enzyme responsible for initiating mitochondrial fatty acid beta-oxidation. Research has associated variations at rs470117 with individual differences in exercise-induced body mass changes, peak lipid oxidation capacity, and traits related to metabolic health.
What each genotype means
Common CPT1B variant profile
This genotype represents the more common allele configuration for this variant. Research suggests this variant may influence mitochondrial fatty acid oxidation efficiency, though findings regarding its specific impact on obesity risk and metabolic health remain mixed and population-dependent. Please consult with a healthcare professional or registered dietitian regarding personalized fitness and nutrition strategies.
This is the most frequent genotype in many European populations, where the minor allele frequency is approximately 0.44.
Heterozygous CPT1B variant profile
Carrying one copy of the minor allele may be associated with variations in how your body manages fatty acid oxidation during physical activity. Some studies have observed that the minor allele (T) is linked to a reduced risk of developing obesity in certain cohorts, though these results are not universal across all populations. Discuss any significant changes to your exercise or dietary regimen with a qualified clinician.
This genotype is common, appearing in a significant portion of the population where the minor allele frequency is approximately 0.44.
Minor allele CPT1B profile
This genotype consists of two copies of the minor allele, which has been investigated for its potential role in metabolic efficiency and obesity risk. While some research indicates a potential association with a reduced risk of obesity, the evidence is limited and may vary based on individual lifestyle and ancestry. Always consult with a healthcare provider before making health decisions based on genetic markers.
This genotype is less common than the CC or CT configurations, occurring in a smaller subset of the population consistent with a minor allele frequency of approximately 0.44.
Genetic Location and Enzymatic Role of CPT1B
The rs470117 polymorphism is located in the carnitine palmitoyltransferase 1B (CPT1B) gene, situated on human chromosome 22q13.33. CPT1B produces the muscle-specific isoform of the CPT1 enzyme, which resides in the outer mitochondrial membrane of skeletal muscle, heart tissue, and brown adipose tissue. This enzyme fulfills the initial and rate-limiting step of long-chain fatty acid transport into mitochondria by converting acyl-CoA into acylcarnitine. Once inside the inner mitochondrial matrix, fatty acids undergo beta-oxidation to generate adenosine triphosphate (ATP). Variations in the CPT1B sequence can influence transcriptional regulation, mRNA stability, or downstream protein kinetics, affecting how efficiently muscle cells shift between carbohydrate utilization and lipid fuel sources during rest and prolonged physical exertion.
Evidence in Exercise Adaptation and Metabolic Research
Scientific investigations have linked CPT1B polymorphisms, including rs470117, to physiological responses in exercise and metabolic health. In human exercise trials evaluating changes in body composition following standardized endurance training regimens, rs470117 emerged within multi-SNP panels associated with differences in body mass reduction and metabolic flexibility. In clinical cohorts examining metabolic syndrome and liver fat distribution, investigators have noted correlations between CPT1B alleles, hepatic steatosis, and circulating lipid levels. For instance, cohort studies in European cohorts have observed that the less frequent allele correlates with variations in fat oxidation rates and protection against excess body adiposity. However, the evidence strength remains moderate: many findings derive from candidate-gene cohorts or multi-gene association panels rather than massive-scale genome-wide association studies (GWAS).
Ancestry and Population Distributions
Allele frequencies for rs470117 demonstrate measurable variability across diverse global populations, though it is widely polymorphic in most cataloged ancestries. In European populations, the minor allele frequency is approximately 0.44, meaning that heterozygous carriers and homozygous individuals of both genotypes are common. Similar distributions are documented across diverse Western cohorts, whereas other ancestral backgrounds cataloged in public genomic resources, such as gnomAD and the 1000 Genomes Project, show modest shifts in relative allele prevalence. Because metabolic alleles often co-segregate with nearby functional markers in strong linkage disequilibrium, the physiological effect of rs470117 can vary depending on broader ancestral genetic backgrounds and environmental exposures.
Interpreting Results: Practical Scope and Limitations
Discovering one's genotype at rs470117 provides insight into subtle inherited predispositions in substrate metabolism, but it does not represent a clinical diagnosis or a barrier to physical fitness. A single genetic variant accounts for only a minor fraction of the total variance in how an individual oxidizes fatty acids or responds to endurance training. Complex phenotypes like exercise efficiency, cardiovascular capacity, and weight management are polygenic, shaped by hundreds of interacting loci along with dietary patterns, total energy balance, sleep, and progressive training volume. Readers should view rs470117 data as an educational perspective on muscle physiology rather than an indicator of athletic limitation or metabolic disease. Any decisions regarding exercise routines or metabolic health should be guided by qualified healthcare professionals.
How common is this variant?
The minor allele at rs470117 has a frequency of approximately 0.44 in European populations, making both homozygous and heterozygous genotypes common. Frequencies remain polymorphic across major global ancestries documented in public reference datasets.
Frequently asked questions
Does my CPT1B rs470117 genotype determine my athletic ability?
No. While rs470117 is statistically associated with subtle variations in fatty acid oxidation and exercise response, it is only one of many hundreds of genetic and lifestyle factors. Training consistency, nutrition, and cardiovascular conditioning play a substantially larger role in determining athletic performance.
What is the primary function of the CPT1B gene?
The CPT1B gene provides instructions for producing carnitine palmitoyltransferase 1B, an enzyme found in muscle and cardiac mitochondria. This enzyme controls the entry of long-chain fatty acids into mitochondria, allowing them to be broken down for cellular energy.
Can rs470117 cause carnitine palmitoyltransferase deficiency?
No. The rs470117 variant is a common, non-pathogenic single nucleotide polymorphism associated with normal metabolic variation. Severe, clinically significant CPT deficiencies are caused by rare, deleterious loss-of-function mutations rather than common consumer SNPs.
Should I change my diet or supplements based on my rs470117 results?
There are no established clinical guidelines that recommend specific diets, carnitine supplementation, or exercise plans tailored solely to the rs470117 genotype. Any significant changes to nutrition, fitness regimens, or clinical management should always be discussed with a doctor or certified sports dietitian.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs470117?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29